An important facet in caring for patients with claudication is the development of a plan for managing the technology available for superficial femoral artery (SFA) and popliteal artery interventions. Although this is a field in evolution, clinical experience and data are emerging that assist the clinician in making informed choices as to the best method of endovascular treatment. Algorithms for SFA and popliteal artery interventions are developing. Methods for assessing a wide range of technologies are discussed. This article reviews the evolution of technology for SFA and popliteal artery interventions, describes the recent developments in data and clinical experiences, and discusses some potential methods of device assessment and incorporation into clinical practice. (J Vasc Surg 2017;66:916-23.) Technology that supports interventions of the superficial femoral artery (SFA) and popliteal artery has evolved significantly in the past 20 years. As devices and the techniques for using them have become more sophisticated, several parallel developments have occurred. Extremely complex lesion morphology that could have been treated only with open surgery a couple decades ago can often be addressed by an endovascular approach. There is a growing and dedicated work force of clinicians that is continuously developing skills and knowledge to support lower extremity interventions. Open surgery is less likely to be the first choice for revascularization of the SFA and popliteal artery. The tools are available to fix most of the complications that are encountered during a procedure. Most lesions can be traversed. The vascular field is maturing with respect to study design and data accumulation. This evolution of the discipline has also resulted in the development and availability of multiple competing and complementary devices for the treatment of SFA and popliteal artery occlusive disease. Randomized trial data are available for balloon angioplasty (percutaneous transluminal angioplasty [PTA]), stents, drug-eluting stents (DESs), stent grafts, and drug-coated balloons (DCBs). The broad array of devices represents needed progress, but it also poses uncertainties about how they should be incorporated into clinical practice. As clinical experience and research accumulate, updated algorithms for SFA and popliteal artery interventions will develop. In the meantime, clinicians must confront the major challenge of assessing these technologies and incorporating them into practice paradigms. The purpose of this article was to review the evolution of technology for SFA and popliteal interventions and recent developments and to discuss some of the practicalities of device assessment and incorporation into clinical practice.
Technology that supports interventions of the superficial femoral artery (SFA) and popliteal artery has evolved significantly in the past 20 years. As devices and the techniques for using them have become more sophisticated, several parallel developments have occurred. Extremely complex lesion morphology that could have been treated only with open surgery a couple decades ago can often be addressed by an endovascular approach. There is a growing and dedicated work force of clinicians that is continuously developing skills and knowledge to support lower extremity interventions. Open surgery is less likely to be the first choice for revascularization of the SFA and popliteal artery. The tools are available to fix most of the complications that are encountered during a procedure. Most lesions can be traversed. The vascular field is maturing with respect to study design and data accumulation. This evolution of the discipline has also resulted in the development and availability of multiple competing and complementary devices for the treatment of SFA and popliteal artery occlusive disease. Randomized trial data are available for balloon angioplasty (percutaneous transluminal angioplasty [PTA] ), stents, drug-eluting stents (DESs), stent grafts, and drug-coated balloons (DCBs). The broad array of devices represents needed progress, but it also poses uncertainties about how they should be incorporated into clinical practice. As clinical experience and research accumulate, updated algorithms for SFA and popliteal artery interventions will develop. In the meantime, clinicians must confront the major challenge of assessing these technologies and incorporating them into practice paradigms. The purpose of this article was to review the evolution of technology for SFA and popliteal interventions and recent developments and to discuss some of the practicalities of device assessment and incorporation into clinical practice.
EVOLUTION OF VASCULAR CARE IN THE SFA AND POPLITEAL ARTERY
In the era when the only broadly functional tool was balloon angioplasty, in the early 1990s and before that, endovascular treatment was usually limited to the simplest lesion morphology. [1] [2] [3] Even then, open surgical bailout was sometimes required. [3] [4] [5] Long-term results were poor, and it was not possible to routinely manage occlusions of the SFA and popliteal artery using endovascular techniques. 5, 6 Balloon angioplasty functions by creating dissections, and post-PTA dissection is associated with higher technical failure, worse patency, and more repeated revascularization. 7, 8 The development of balloon-expandable stents was a major milestone in the advancement of vascular care, but these were not particularly effective in the SFA and popliteal artery. 9 Self-expanding nitinol stents dramatically improved what could be offered to patients requiring treatment of the SFA and popliteal artery. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] The compressible, flexible nature of these stents was more consistent with the highly dynamic infrainguinal arteries, and they could be used to manage the types of dissections produced by angioplasty, especially in treating occlusions and long lesions. 20, 21 Since the first clinically available self-expanding nitinol stent was Food and Drug Administration approved in 2009, multiple additional complementary developments have taken place that have changed the field and are discussed briefly. Ultimately, a number of different competing stents were developed and multiple trials were performed to evaluate them, usually comparing the stent with balloon angioplasty or with angioplasty optimal performance criteria (OPC ; Table) . [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Self-expanding stents improved on the patency that could be expected from angioplasty alone. The peak time frame for restenosis after balloon angioplasty is 6 months; with stents, the peak of restenosis is lower, and it is extended to approximately 12 months. 22, 23 However, new problems were introduced, including in-stent restenosis, stent thrombosis, and stent fracture. 24, 25 Partial solutions to some of these problems have emerged.
The concept of the covered stent or stent graft was tested in several randomized trials in hopes of reducing in-stent restenosis. [26] [27] [28] A paclitaxel-coated stent was introduced. 14 The concept of drug delivery directly to the vessel wall of the SFA and popliteal artery through balloon angioplasty was also introduced and has shown promise. 7, 29, 30 After many years of applying solutions to the SFA and popliteal artery that are based on mechanical solutions, cellular manipulation is now possible with the advent of drug delivery. The concept is that an antiproliferative medication could have a long-term beneficial effect in reducing the cellular response and inflammation that usually occur in response to intervention. The era of drug delivery to improve the potential for longer term patency has arrived. DESs and DCBs have been shown to have an effect that is sustained beyond the often-cited 1-year time frame for SFApopliteal studies. 31, 32 Most occlusions of the SFA and popliteal artery can be traversed, even very long or heavily calcified lesions, because of further device and technique development in recent years. Devices that have made traversal of occlusions more readily reproducible include chronic total occlusion wires and catheters, re-entry devices, crossing catheters, and tools for retrograde access. However, we are still challenged with the ability to extend the patency of endovascular procedures to be competitive with femoral-popliteal bypass. The field continues to evolve and improve, but challenges remain, including reliable long-term patency, clear guidelines for management of calcification, and device comparisons for efficacy.
Long-term patency after intervention remains a question under active clinical research, and data beyond 12 months are developing. Patency data from both balloon angioplasty procedures and stent procedures demonstrate that beyond 1 year, the likelihood is high that there will be continued loss of patency. Because many SFA interventions are performed in patients with claudication and life span in claudicators is measured in decades, this long term is essential. practice, but all vascular clinicians face this issue, and it will continue to be the subject of ongoing discussion.
ASSESSMENT OF CURRENT TECHNOLOGIES
Balloon angioplasty. Balloon angioplasty has been perfected during five decades and has been a key treatment option for SFA and popliteal lesions. As a result of more efficacious options being developed, balloon angioplasty is less commonly used as a stand-alone treatment option. The technique of balloon angioplasty does influence patency and dissection. Angioplasty alone is a suboptimal mechanical means of gaining adequate lumen and avoiding dissection. Balloon angioplasty may still be used in the shortest and least complex lesions. The results of PTA from the control arms of three randomized trials showed that with a mean lesion length of 8.7 cm, 12-month duplex ultrasound-derived patency was 28%. 36 In the recently completed randomized controlled trials of PTA vs DCBs, the patency of balloon angioplasty was 52.6% in the Lutonix paclitaxelcoated balloon for the prevention of femoropopliteal restenosis (LEVANT 2) trial (mean lesion length, 6.3 cm) and 52.4% in the IN.PACT trial (mean lesion length, 8.8 cm). 29, 30 This can be considered the best result that can be achieved with PTA. Balloon angioplasty alone, On the horizontal axis is plotted the mean lesion length for the corresponding trials and treatment groups. The PTA data are composed of numerous randomized trials vs bare nitinol stents, drug-eluting stents (DESs), and drug-coated balloons (DCBs) and the VIVA optimal performance criteria (OPC), which were composed of three sets of raw trial data. The stent data are composed of studies that compared stents with balloon angioplasty or OPC and include self-expanding nitinol stents, a woven nitinol stent, and a DES. Of note is that the 1-year patency for stent is higher than that for PTA when indexed against lesion length. Most of these data were collected in TransAtlantic Inter-Society Consensus A and B lesions. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] 29, 30, [37] [38] [39] [40] Each of these trials is different and cannot be directly compared. Each trial has varying design and inclusion criteria and has different numbers of patients with risk factors that may influence results. Lesion length is only one comparative factor.
even for short lesions, may not be a reasonable option for stand-alone treatment in the future. Balloon angioplasty fails because of acute dissection, residual stenosis, and later intimal hyperplasia. The results of using balloon angioplasty in numerous trials are presented in Fig 1. 
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Nitinol stents. Numerous self-expanding nitinol stents of varying designs have been approved by the Food and Drug Administration (Table) . The stent arms of various trials are also shown in Fig 1. Most of the data were collected in the treatment of TransAtlantic Inter-Society Consensus A and B lesions. The improvement in patency, when adjusted for lesion length, has an advantage over the results of PTA. The availability of stents was a major advance in SFA and popliteal artery intervention. However, a similar patency pattern is present for both PTA and stentsddecreased patency with progressively longer lesions. In-stent restenosis became a new type of lesion requiring treatment. This is particularly difficult to treat with generally poor results, especially if the stent goes on to occlusion. Freedom from recurrent in-stent restenosis at 1 year after treatment of an occluded stent is 23% to 35%, and occluded stents are most likely to be associated with severe stent fractures. 24, 25 Factors that correlate with in-stent restenosis include overlapping of stents, stent fracture, stent material, location, and length of the stented segment. Constant interaction between the mobile lower extremity artery and the implanted stent likely promotes in-stent restenosis. This is a cellular response that may occur anywhere along the length of the stent and not necessarily at the location where the original lesion was the worst.
Stent grafts. Stent grafts were developed as a potential answer for in-stent restenosis, and several studies were conducted in longer lesions (Fig 2) . [26] [27] [28] The pattern of decreasing patency with longer lesions that was demonstrated with balloon angioplasty and bare-metal stents was also evident with stent grafts. Stent graft failure was associated with edge restenosis, graft oversizing, and a risk of stent graft thrombosis.
DESs. Another option for managing in-stent restenosis is a drug-coated stent or DES. If the cellular response of intimal hyperplasia could be inhibited, perhaps the risk of in-stent restenosis could be substantially diminished. Two early projects on DES (Sirolimus-Coated Cordis SelfExpandable Stent [SIROCCO] and Superficial Femoral Artery Treatment with Drug-Eluting Stents [STRIDES]) failed to show a significant advantage in patency. 41, 42 However, a subsequent device, Zilver PTX, showed better patency than PTA and also better patency than bare-metal Zilver stents that were placed for the complications of angioplasty. 14, 32 Another device is in clinical trials, also using paclitaxel. 26-28 Each of these trials is different and cannot be directly compared. Each trial has varying design and inclusion criteria and has different numbers of patients with risk factors that may influence results. Lesion length is only one comparative factor. DES, Drug-eluting stent.
could improve patency. 7 This prompted the development of numerous DCB programs. Two randomized trials were subsequently published that showed improved patency compared with PTA (Fig 3) . 29, 30 In this situation, in addition to mechanical manipulation, drug is transferred to the wall of the artery. When indexed for lesion length, 1-year patency for DCB is consistent with results achieved with stent placement. Drug-mediated therapies have enhanced the long-term patency of endoluminal coronary revascularization and have changed the treatment paradigm for coronary artery disease. Paclitaxel is a common chemotherapeutic agent and was one of the early agents used in the coronary arteries. Paclitaxel is a cytostatic agent that acts on microtubules. 43 A single dose of 70 mg has no adverse effect. The approximate maximum dose that can be loaded on a balloon at 3.5 mg/mm 2 is 10 mg. The paclitaxel is adherent to the balloon surface using an excipient. The more crystalline preparation of adherent paclitaxel is more readily transferred to the vessel wall during balloon inflation. Paclitaxel crystals taken up by the vessel wall become slowly dissolving particles that permit drug to be released during a period of months. The optimal drug dose is not known, but paclitaxel is considered to be therapeutic at doses of 2 to 4 mg/mm 2 . The ideal excipient is not known, but several different excipients have been used with success, including urea, polysorbate and sorbitol, polyethylene glycol, citrate ester, and others. Only a small percentage of the paclitaxel is ultimately transferred to the vessel wall, probably <20%, the remainder being lost during balloon insertion or in transit to the lesion site, washed into the runoff, or retained on the balloon.
As the era of drug delivery develops, a major remaining challenge is achieving better results in patients with TransAtlantic Inter-Society Consensus C and D lesions of the SFA and popliteal artery. Some recently published prospective, nonrandomized data with long lesions suggest that there is promise for DCBs (Fig 4) . In treating lesions with mean lesion lengths of 19 to 25 cm, the 1-year duplex ultrasound-derived patency ranged from 76% to 83%. [44] [45] [46] These results are better than those demonstrated with stents or stent grafts and dramatically better than those of plain balloon angioplasty. Use of DCBs for long lesions also requires increased need for stents, and most postangioplasty dissection repair has been focused on focal treatment of defects. In summary, progress is being made to improve the patency of the interventions we offer for SFA and popliteal occlusive disease in claudicators. An evolution of technologies has occurred. PTA may not be an acceptable stand-alone procedure in most patients. PTA and selective stent placement or primary stenting has been 29, 30 Each of these trials is different and cannot be directly compared. Each trial has varying design and inclusion criteria and has different numbers of patients with risk factors that may influence results. Lesion length is only one comparative factor. In particular, the DCB randomized trials were designed to consider a poor result of predilatation to be a screen failure and these patients were not included in the trial. DES, Drug-eluting stent; PTA, percutaneous transluminal angioplasty; RCT, randomized controlled trial. the paradigm in the SFA for the past several years. It is highly likely that we will move toward DCB plus focal dissection repair for most SFA lesions and that stents or DESs will be selected for use in patients with the worst disease morphology or those presenting with recurrent lesions.
INCORPORATING TECHNOLOGY INTO PRACTICE
Multiple choices must be made to determine which therapy to use in a given case and in what order technologies should be employed in the broader vascular practice. Some formalized method of evaluating technologies is extremely helpful. In larger groups, the collective experience and opinions of many practitioners can be used to help make decisions. Kaiser Permanente is a large group with >100 vascular surgeons, and the organization uses several mechanisms that help with decision-making. A New Technology Committee composed of physicians, engineers, and scientists evaluates major new classes of technologies and makes nonbinding recommendations about how they might be used. Some examples include closure devices and robotics. The work product is intended to educate and to inform the entire health care organization about recent advances. A National Product Council is composed of physicians, administrators, and purchasing experts. This organization is multidisciplinary and is responsible for contracts to purchase supplies and devices. Typically, two vendors with overlapping portfolios are selected from numerous potential suppliers. When there is need to obtain a product or device that is not on contract, there is an exception process. This is a request to a committee made up of physicians, and the request is primarily focused on how the desired item can perform a function or add a benefit not realized from existing approved devices. In addition, we have established a local Hawaii Region Vascular Surgical Team. This includes a monthly meeting to assess local needs, to manage inventory, to discuss new devices and projects, and to seek to minimize expired goods. We review expired goods, par levels, various aspects of the inventory, and any deficiencies that we may have experienced. When an item is added to the inventory, the question of whether some other item has been replaced is always considered. We request new items as a department, not as individual practitioners. When one physician is strongly interested in purchasing a new or different device, it is up to that physician to present it to the other physicians in the department, and the subsequent decision is made as a group. We have also performed side-by-side comparisons when appropriate. Some examples include portable ultrasound, atherectomy, and varicose vein treatments. The key feature is that some structure for evaluating and One-year patency including drug-coated balloons (DCBs) for long lesions. Recent prospective study data using DCBs in long lesions (TransAtlantic Inter-Society Consensus C and D) are demonstrated. This suggests than when indexed for lesion length, DCBs produce results in long lesions that are as good as or better than what can be expected for stents or stent grafts in similar length lesions. Each of these trials is different and cannot be directly compared. Each trial has varying design and inclusion criteria and has different numbers of patients with risk factors that may influence results. Lesion length is only one comparative factor. In particular, the DCB randomized trials were designed to consider a poor result of predilatation to be a screen failure and these patients were not included in the trial. The long lesion DCB trials were not randomized and were carried out in a limited number of centers. DES, Drug-eluting stent; PTA, percutaneous transluminal angioplasty; RCT, randomized controlled trial. using new devices is extremely helpful, especially given the wide array of choices, the high cost of devices, and the variability of practice.
CONCLUSIONS
This article reviews the evolution of technology for SFA and popliteal artery interventions, describes recent developments, and discusses some of the practicalities and challenges of device assessment and incorporation into practice faced by clinicians. Randomized trial data are available for balloon angioplasty, stents, DESs, stent grafts, and DCBs. As clinical experience and research accumulate on different modes of definitive therapy, algorithms for SFA and popliteal artery interventions in patients with claudication will likely develop. In the interim, clinicians must assess these technologies and find methods of incorporating them into practice.
